Trial Profile
Tocilizumab treatment for induction of remission in patients with idiopathic retroperitoneal fibrosis (TOCIRET)
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Jun 2018
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Retroperitoneal fibrosis
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms TOCIRET
- 01 Jun 2018 New trial record